Radiogenomics based survival prediction of small-sample glioblastoma patients by multi-task DFFSP model
Author:
Fu Xue1, Chen Chunxiao1, Chen Zhiying1, Yu Jie1, Wang Liang1
Affiliation:
1. Department of Biomedical Engineering , 47854 Nanjing University of Aeronautics and Astronautics , Nanjing , China
Abstract
Abstract
In this paper, the multi-task dense-feature-fusion survival prediction (DFFSP) model is proposed to predict the three-year survival for glioblastoma (GBM) patients based on radiogenomics data. The contrast-enhanced T1-weighted (T1w) image, T2-weighted (T2w) image and copy number variation (CNV) is used as the input of the three branches of the DFFSP model. This model uses two image extraction modules consisting of residual blocks and one dense feature fusion module to make multi-scale fusion of T1w and T2w image features as backbone. Also, a gene feature extraction module is used to adaptively weight CNV fragments. Besides, a transfer learning module is introduced to solve the small sample problem and an image reconstruction module is adopted to make the model anatomy-aware under a multi-task framework. 256 sample pairs (T1w and corresponding T2w MRI slices) and 187 CNVs of 74 patients were used. The experimental results show that the proposed model can predict the three-year survival of GBM patients with the accuracy of 89.1 %, which is improved by 3.2 and 4.7 % compared with the model without genes and the model using last fusion strategy, respectively. This model could also classify the patients into high-risk and low-risk groups, which will effectively assist doctors in diagnosing GBM patients.
Funder
National Natural Science Foundation of China
Publisher
Walter de Gruyter GmbH
Reference32 articles.
1. Ostrom, QT, Gittleman, H, Truitt, G, Boscia, A, Kruchko, C, Barnholtz-Sloan, JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol 2018;20:iv1–86. https://doi.org/10.1093/neuonc/noy131. 2. Yang, JY, Kong, SH, Ahn, HS, Lee, HJ, Jeong, SY, Ha, J, et al.. Prognostic factors for reoperation of recurrent retroperitoneal sarcoma: the role of clinicopathological factors other than histologic grade. J Surg Oncol 2015;111:165–72. https://doi.org/10.1002/jso.23783. 3. Stupp, R, Hegi, ME, Mason, WP, Bent, MJ, Taphoorn, MJ, Janzer, RC, et al.. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66. https://doi.org/10.1016/s1470-2045(09)70025-7. 4. Saurabh, R, Nandi, S, Sinha, N, Shukla, M, Sarkar, RR. Prediction of survival rate and effect of drugs on cancer patients with somatic mutations of genes: an AI‐based approach. Chem Biol Drug Des 2020;96:1005–1019. https://doi.org/10.1111/cbdd.13668. 5. Buchwald, ZS, Tian, S, Rossi, M, Smith, GH, Switchenko, J, Hauenstein, JE, et al.. Genomic copy number variation correlates with survival outcomes in WHO grade IV glioma. Sci Rep 2020;10:1–10. https://doi.org/10.1038/s41598-020-63789-9.
|
|